Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Dermedic Jacek Zdybski

Verified siteinfo

Poland Henryka Sienkiewicza 65/14/II, 27-400 Ostrowiec Swietokrzyski, Poland

  • 2 trials recruiting
  • Hidradenitis · Dermatitis atopic · Psoriasis
  • Adults and children

About Specializations

Dermedic Jacek Zdybski in Ostrowiec Swietokrzyski, Poland specialises in clinical trials of conditions such as Hidradenitis, Dermatitis atopic, Psoriasis, Vitiligo, and other specialisations. This site conducts important research.

Main research areas of the site

Dermatology and Skin Disorders

The medical center is at the forefront of dermatology research, with a particular focus on Prurigo Nodularis. This chronic skin condition is characterized by intensely itchy nodules, and the center is dedicated to advancing treatment options to improve patient quality of life.

  • Innovative therapies for chronic skin conditions
  • Advanced understanding of skin lesion pathophysiology
  • Patient-centered approaches to itch management

Through ongoing research, the center is exploring the efficacy of novel treatments like povorcitinib, aiming to alleviate symptoms and enhance skin health in affected individuals.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Henryka Sienkiewicza 65/14/II27-400 Ostrowiec SwietokrzyskiPoland
Open in maps ↗
Recruiting now
2 trials
Conditions studied
4
Partner status
Verified site

More sites in Ostrowiec SwietokrzyskiPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

11 clinical trials

Psoriasis

Recruiting

Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Psoriasis

Recruiting

Study on Tildrakizumab and Etanercept for Children Aged 6 to 17 with Moderate to Severe Plaque Psoriasis

Registered drug
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Etanercept
  • Sponsor:Sun Pharmaceutical Industries Limited

Dermatitis atopic

Not yet recruiting

Study to evaluate ATI-045 injection compared to placebo in adults with moderate to severe atopic dermatitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:HUMANISED IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST THYMIC STROMAL LYMPHOPOIETIN
  • Sponsor:Aclaris Therapeutics Inc.

Dermatitis atopic

Not recruiting

A study testing BFB759 compared to placebo to evaluate effectiveness and safety in adult patients with atopic dermatitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BFB759
  • Sponsor:Bluefin Biomedicine Inc.

Psoriasis

Not recruiting

Comparison of zasocitinib and deucravacitinib in adults with moderate to severe plaque psoriasis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Takeda Development Center Americas Inc.

Vitiligo

Not recruiting

Study on the Effectiveness of Povorcitinib for Adults with Nonsegmental Vitiligo

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Hidradenitis

Not recruiting

A study to evaluate the effectiveness and safety of BFB759 in adults with moderate to severe hidradenitis suppurativa

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BFB759
  • Sponsor:Bluefin Biomedicine Inc.

Hidradenitis

Not recruiting

A Study to Evaluate the Safety and Effectiveness of Ritlecitinib Tosilate in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Pfizer Inc.

Hidradenitis

Not recruiting

Study of Bimekizumab for Children and Adolescents with Moderate to Severe Hidradenitis Suppurativa

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Dermatitis atopic

Not recruiting

Study on Tralokinumab and Topical Corticosteroids for Children and Infants with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Tralokinumab
  • Sponsor:Leo Pharma A/S

Hidradenitis

Not recruiting

Study on the Long-Term Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
  • Sponsor:Incyte Corp.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.